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Human sera from the United States, Thailand, and
sub-Saharan Africa and chimpanzee sera were tested for
neutralizing antibodies to 3 chimpanzee adenoviruses.
Antibodies were more common in humans residing in sub-
Saharan Africa than in humans living in the United States or
Thailand. This finding suggests cross-species transmission
of chimpanzee adenoviruses.
V
accines to HIV-1 are needed to stem further spread of
the HIV pandemic. One vaccine modality that has
shown promise is based on adenovirus vectors of human
serotype 5 (AdHu5) (1–3). However, immune responses
induced by AdHu5 vectors are reduced by preexisting
AdHu5-neutralizing antibodies found in humans in the
United States (4–7).
The Study
To circumvent the negative effect of preexisting immu-
nity to common human serotypes of adenoviruses on the
efficacy of adenovirus vaccine carriers, we developed vec-
tors based on chimpanzee-derived adenoviruses C68, C6,
and C1 (8). We previously showed that neutralizing anti-
bodies to chimpanzee adenoviruses are rarely found in US
residents (6). Because vaccines to HIV-1 are most urgent-
ly needed in sub-Saharan Africa, we evaluated the preva-
lence of neutralizing antibodies to chimpanzee
adenoviruses in sera from humans residing in 3 sub-
Saharan countries with natural habitats for chimpanzees:
Nigeria, Cameroon, and Côte d’Ivoire. Sera from captive
chimpanzees in the United States and human sera from
Thailand and the United States, including samples from
persons with known exposures to chimpanzees, were test-
ed for comparison.
Neutralizing antibodies to AdHu5 were found in most
serum samples from Africa and Thailand. Percentages of
antibodies to AdHu5 were higher in serum samples from
Africa and Thailand than in serum samples from the
United States (Table 1). Titers to AdHu5 were comparable
in serum samples from the United States and sub-Saharan
Africa but were higher in the control group from Thailand
(Table 2).
Neutralizing antibodies to AdC68, AdC6, and AdC1
were rare in sera from the United States and Thailand, with
prevalence rates from 1.5% to 4% (Figure). Most positive
samples had titers <80. Of 200 samples from Thailand,
only 6 had high titers: 4 to AdC6 and 2 to AdC1. None of
the samples from 50 US zoo workers, including those who
reported regular contact with primates, had detectable anti-
bodies to chimpanzee adenoviruses.
In contrast, serum samples from sub-Saharan African
cohorts had higher prevalences of neutralizing antibodies
to chimpanzee adenoviruses (Figure, Table 1). Samples
from persons living in Cameroon and Nigeria showed a
higher prevalence of neutralizing antibodies to AdC6 and
AdC1. Titers of neutralizing antibodies to AdC6 and AdC1
were high, and samples were positive at dilutions >1:80.
When compared with sera from Nigeria and Cameroon,
sera from Côte d’Ivoire had a different pattern of antibod-
ies reactive to the chimpanzee adenoviruses; prevalence
rates were low to AdC1 but higher to AdC68 and AdC6.
Although most samples had low to moderate titers, sever-
al samples had titers ≥80. No association was found
between neutralizing antibodies to AdC68, AdC6, and
AdC1 in any of the human samples tested, and only a few
human serum samples had neutralizing antibodies to >1
chimpanzee adenovirus (data not shown). One serum sam-
ple from Cameroon neutralized all 3 chimpanzee aden-
oviruses and had titers of 20 to AdC68 and 160 to AdC6
and AdC1.
Circulating neutralizing antibodies to AdHu5 were
found in 44% of captive US chimpanzees; titers in chim-
panzee samples were comparable to those in human sera,
suggesting that AdHu5 can readily cause an infection in
captive chimpanzees. The prevalence of antibodies to
AdC6 and AdC68 was high and exceeded that of antibod-
ies to AdC1 (Table 1). Titers to AdC68 and AdC6 were
higher in chimpanzees than in humans, but titers to AdC1
in both species were similar (Table 2).
Conclusions
Our data show that as expected, neutralizing antibodies
to chimpanzee adenoviruses are rarely found in humans
residing in the United States or Thailand. In contrast, their
prevalence is higher in human sera from sub-Saharan
Africa, where hunting and butchering of nonhuman pri-
mates for food are widespread and eating bush meat is com-
DISPATCHES
1596 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 12, No. 10, October 2006
*The Wistar Institute, Philadelphia, Pennsylvania, USA;
†University of Pennsylvania School of Medicine, Philadelphia,
Pennsylvania, USA; and ‡Centers for Disease Control and
Prevention, Atlanta, Georgia, USAmon (11). Different prevalence rates of neutralizing anti-
bodies to the 3 chimpanzee adenoviruses in human samples
from the 3 African countries tested may reflect different
infection rates in chimpanzees residing in these areas. 
Cameroon, Gabon, and Republic of Congo are home to
most Central African common chimpanzees (Pan
troglodytes troglodytes). Most Western common chim-
panzees (P. t. verus) inhabit Côte d’Ivoire and Guinea. The
rare Nigeria chimpanzee (P. t. vellerosus) is found only in
eastern Nigeria and western Cameroon, and Eastern
African common chimpanzees (P. t. schweinfurthii) reside
in a range from Central African Republic and the
Democratic Republic of the Congo through western
Uganda and Tanzania. No clear association was found
between chimpanzee subspecies and neutralizing antibod-
ies to different chimpanzee adenoviruses. Nevertheless,
most samples were from P. t. verus, and only a limited
number of samples were from P. t. troglodytes (n = 4) and
P. t. schweinfurthii (n = 3). No samples from P. t. vellero-
sus were tested. In addition, the chimpanzee samples eval-
uated in the study were from animals kept in captivity and
thus may not provide information on distribution of these
viruses in free-ranging animals.
Increased prevalence of neutralizing antibodies to
chimpanzee adenoviruses in sub-Saharan Africa may
reflect cross-species transmission of these viruses from
chimpanzees to humans. If transmission occurs, human-to-
human spread of chimpanzee adenoviruses might further
contribute to the comparatively high seroprevalence seen
in equatorial Africa. Although we have no direct proof for
viral cross-species transmission, this process has been pre-
viously described for other chimpanzee viruses. For exam-
ple, the AIDS epidemic is believed to have originated from
simian immunodeficiency virus–infected chimpanzees
(12). Another chimpanzee retrovirus, simian foamy virus,
has been reported to infect persons exposed to primates at
zoos and research centers (13) and to infect Bantus in
Cameroon (14). Chimpanzee adenoviruses do not appear
to spread easily to humans through occupational contact
with primates because none of the 23 persons who had rou-
tine exposure to primates, including chimpanzees, had
serologic evidence of exposure despite the high prevalence
of antibodies to chimpanzee adenoviruses in captive US
chimpanzees.
Use of chimpanzee adenovirus vectors as vaccines for
HIV-1 would require that most persons at high risk for
HIV-1 infection lack neutralizing antibodies to these aden-
oviruses because such antibodies impair induction of
transgene product-specific immune responses (4,5). Even
in countries where chimpanzees are endemic, neutralizing
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humans than those directed to AdHu5, which is currently
in clinical trials as a vaccine for HIV-1 antigens in a vec-
tored and replication-defective form. An alternative human
serotype is AdHu35, which is being developed as a poten-
tial vaccine against HIV-1 (15). Prevalence rates to
AdHu35 are low in the United States and Europe (<5%);
however, rates are markedly higher (<20%) in equatorial
Africa (15). 
Although neutralizing antibodies to chimpanzee aden-
oviruses are also relatively more common in human sera
from sub-Saharan Africa, they are found less frequently
than antibodies to AdHu5 or AdHu35. Nonetheless,
increased prevalence of neutralizing antibodies to aden-
oviruses in countries that are hardest hit by the AIDS pan-
demic needs to be taken into account in the design of
vaccines based on chimpanzee adenovirus vectors. Vectors
derived from other species are being developed and may
provide additional or alternative vaccine carriers.
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Figure. Prevalence of neutralizing antibody titers to chimpanzee
adenoviruses. Percentages of negative samples are not shown.
Left column: Cameroon, black bars; Côte d'Ivoire, white bars;
Nigeria: gray bars. Middle column: Thailand, black bars; US con-
trols, white bars; US zoo keepers or animal handlers, gray bars.
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listeriosis, and takes place every 3 to 4
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young scientists. Plenary sessions and
symposia will feature internationally
renowned Listeria researchers. 
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